INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Decoding Antimicrobial Resistance: Mechanisms, Evolution, and Therapeutic Challenges

Ranajeet Patil*[1], Shivprasad Dhage[2]

[1]*MBBS Second Year Department of Microbiology, Virology, Immunology Fergana Medical Institute of Public health, Uzbekistan*
[2]*Assistant Professor, Department of Microbiology, Virology and immunology, fergana Medical Institute of Public health, Uzbekistan.*

ARTICLE INFO

Published: 12 May. 2026
Keywords:
Antimicrobial resistance; β-lactamase; biofilm; efflux pumps; horizontal gene transfer; CRISPR-Cas; phage therapy; stewardship; multidrug resistance; carbapenemase; mobile genetic elements; One Health
DOI:
10.5281/zenodo.20132733

ABSTRACT

Antimicrobial resistance (AMR) has emerged as one of the gravest threats to global public health in the twenty-first century, challenging the fundamental foundations of modern clinical medicine. The progressive erosion of antibiotic efficacy across diverse pathogenic species demands a rigorous understanding of the molecular events that confer resistance, the evolutionary pressures that sustain it, and the clinical consequences that follow. This comprehensive narrative review synthesises evidence from primary research articles, systematic reviews, and authoritative international guidelines published between 2010 and 2025. Literature was retrieved from PubMed, Scopus, and Web of Science using pre-specified search terms relating to AMR mechanisms, epidemiology, therapeutic strategies, and surveillance frameworks. The review delineates six principal resistance mechanisms: enzymatic drug inactivation (particularly β-lactamase-mediated hydrolysis including extended-spectrum β-lactamases and carbapenemases), drug target modification, efflux pump-mediated drug extrusion, reduced membrane permeability through porin loss, biofilm formation, and horizontal gene transfer (HGT). Evolutionary analysis reveals that genetic mutation, environmental selection pressure, and mobile genetic elements (MGEs) collectively drive AMR dissemination across species boundaries. Clinically, AMR is responsible for approximately 1.27 million direct deaths annually and threatens the viability of surgical procedures, cancer chemotherapy, and organ transplantation. Emerging countermeasures—phage therapy, antimicrobial peptides, CRISPR-based gene editing tools, novel β-lactamase inhibitor combinations, and artificial intelligence-guided drug discovery—offer substantive promise, though significant translational barriers persist.

***Corresponding Author:** Ranajeet Patil
Address: *MBBS Second Year Department of Microbiology, Virology, Immunology Fergana Medical Institute of Public health, Uzbekistan*
Email ✉: ranajeetpatil6@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

The history of infectious disease management underwent a paradigm shift with Alexander Fleming's serendipitous identification of penicillin in 1928, an event that inaugurated the modern antibiotic era and fundamentally transformed the prognosis of previously lethal bacterial infections [1]. The subsequent "golden era" of antibiotic discovery spanning the 1940s through 1960s furnished clinicians with a broad therapeutic arsenal encompassing β-lactams, aminoglycosides, tetracyclines, macrolides, chloramphenicol, and glycopeptides [2]. Yet, scarcely had these compounds entered clinical practice before resistance phenotypes were documented, foreshadowing the contemporary crisis that now imperils the entire edifice of evidence-based medicine. Antimicrobial resistance is formally defined as the capacity of a microorganism—encompassing bacteria, viruses, fungi, and parasites—to sustain viability and replicate in the presence of a concentration of antimicrobial agent sufficient to inhibit or eliminate susceptible strains [3]. From a clinical perspective, AMR manifests as a diminution of minimum inhibitory concentration (MIC) thresholds, leading to therapeutic failure, protracted hospitalisation, elevated morbidity, and preventable mortality. Resistance may be intrinsic, arising from the inherent structural or biochemical attributes of a species, or acquired, resulting from genetic mutations or the lateral transfer of resistance determinants from exogenous sources [4]. Contemporary epidemiological surveillance has revealed an alarming global trajectory. A landmark analysis by the Global Research on Antimicrobial Resistance (GRAM) consortium, published in The Lancet, estimated that bacterial AMR was directly responsible for 1.27 million deaths in 2019, with a further 4.95 million deaths associated with resistance-related complications—figures that exceed the annual mortality attributable to HIV/AIDS and malaria combined [5]. These projections intensify considerably toward 2050, with some models forecasting 10 million AMR-attributable fatalities annually in the absence of decisive global action, representing an economic loss potentially exceeding USD 100 trillion [6]. The epidemiological landscape is further complicated by several converging factors. Pharmaceutical attrition in the antibiotic development pipeline has been dramatic: the number of novel antibiotics entering clinical development has declined precipitously over three decades, driven by unfavourable return on investment, formidable scientific obstacles in target identification, and stringent regulatory requirements [7]. Simultaneously, the inappropriate and injudicious use of antimicrobials—estimated to account for 30–50% of all antibiotic prescriptions globally—exerts continuous selective pressure on microbial populations, accelerating the emergence of resistant variants [8]. The widespread administration of antibiotics in veterinary medicine and agricultural production, wherein approximately 80% of antibiotics sold in the United States are directed toward livestock for growth promotion and prophylaxis, generates additional environmental reservoirs of resistance genes that may ultimately transfer to human pathogens [9]. Against this backdrop, the present review undertakes a systematic examination of the biochemical mechanisms underpinning AMR, the evolutionary processes that drive its emergence and dissemination, the clinical and economic consequences of therapeutic failure, and the current landscape of strategies aimed at curbing the resistance pandemic. Special attention is devoted to emerging technologies—including CRISPR-Cas platforms, phage therapy, antimicrobial peptides, and artificial intelligence-

assisted drug discovery—whose translational potential may redefine the therapeutic paradigm in coming decades. By integrating mechanistic, evolutionary, and translational dimensions, this review aims to provide a consolidated resource for researchers, clinicians, and policymakers engaged in the global struggle against antimicrobial resistance.

2. Causes and Drivers of Antimicrobial Resistance

2.1 Inappropriate Antibiotic Use and Prescribing Patterns

Injudicious antibiotic prescribing represents the single most consequential anthropogenic driver of AMR evolution. Population-level studies consistently document that 30–50% of antibiotic prescriptions lack appropriate clinical indication, with a significant proportion directed toward viral respiratory tract infections for which no bacteriological benefit exists [10]. Within intensive care units, estimates suggest that 30–60% of antibiotic courses are unnecessary, inappropriate in spectrum, or suboptimally dosed relative to the causative pathogen's susceptibility profile [8]. Such exposures create sub-therapeutic antibiotic concentrations that selectively favour bacterial variants with even marginally enhanced intrinsic tolerance, providing the evolutionary substrate from which high-level clinical resistance subsequently emerges through stepwise mutational accumulation [11]. The phenomenon of antibiotic overprescribing is further exacerbated by patient-driven demand, inadequate clinician training in diagnostic stewardship, and the widespread availability of antimicrobials without prescription in low- and middle-income countries (LMICs). In these settings, the absence of robust regulatory frameworks enabling over-the-counter antibiotic purchase without medical oversight dramatically broadens the pool of selective pressure exerted on community-dwelling bacterial populations [12].

2.2 Non-Human Antimicrobial Use and One Health Considerations

The One Health framework, which recognises the ecological interconnectedness of human, animal, and environmental health, is indispensable for understanding AMR epidemiology at a systems level. In agricultural settings, the routine administration of subtherapeutic antibiotic doses to livestock for growth enhancement generates sustained selection pressure that promotes resistance gene acquisition in commensal and zoonotic bacteria [13]. Alarmingly, up to 90% of administered antibiotics are excreted unmetabolised in animal waste, entering soil and water systems and exposing environmental microbial communities to clinically significant antibiotic concentrations. This environmental antibiotic residue reservoir functions as an underappreciated incubator of novel resistance determinants that may subsequently transfer to human-associated pathogens through complex ecological networks [14]. Molecular epidemiological studies have demonstrated bidirectional transfer of resistant strains and ARGs between livestock, food products, and human carriers, with multidrug-resistant Salmonella, Campylobacter, and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae serving as paradigmatic examples of zoonotic resistance transmission [15]. The contamination of potable water supplies and irrigation systems with antibiotic-laden agricultural runoff further amplifies environmental ARG reservoirs, creating ecologically distributed networks of resistance gene circulation that conventional infection control measures cannot adequately intercept [16].

2.3 Surveillance Gaps and Diagnostic Limitations

Effective AMR containment is fundamentally dependent on timely, granular surveillance data that inform prescribing practices and public health interventions. However, substantial global gaps in AMR surveillance infrastructure—particularly in LMICs—critically impede the development of evidence-based response strategies [17]. The absence of routine antimicrobial susceptibility testing (AST) in resource-limited healthcare settings prevents accurate characterisation of local resistance patterns, resulting in empirical prescribing decisions guided by outdated or geographically irrelevant regional data. Molecular diagnostic platforms capable of rapid pathogen identification and resistance gene characterisation remain unaffordable and operationally unfeasible in many high-burden settings, further widening the diagnostic gap that sustains inappropriate prescribing and delayed appropriate therapy [18].

3. Biochemical Mechanisms of Antimicrobial Resistance

Prior to examining resistance mechanisms, it is instructive to appreciate the principal molecular targets exploited by antimicrobial agents. Broadly, antibiotics exert their bacteriostatic or bactericidal activity through inhibition of cell wall biosynthesis, disruption of cell membrane integrity, blockade of protein synthesis at the 30S or 50S ribosomal subunit, interference with nucleic acid replication and transcription, or disruption of key metabolic pathways such as folate biosynthesis [19]. Table 3 summarises the major antibiotic classes, their molecular targets, and associated resistance mechanisms.



Figure 1. Mechanisms of action of antimicrobial agents across key bacterial cellular targets.

Table 3. Classification of Antimicrobial Agents: Mechanisms of Action and Primary Resistance Mechanisms

Antibiotic Class	Mechanism of Action	Key Agents	Major Resistance Mechanisms
β-Lactams	Inhibition of penicillin-binding proteins (PBPs); cell wall synthesis disruption	Penicillins, Cephalosporins, Carbapenems, Monobactams	β-lactamase production, PBP alteration, efflux
Glycopeptides	Inhibition of peptidoglycan cross-linking via D-Ala-D-Ala binding	Vancomycin, Teicoplanin, Dalbavancin	D-Ala-D-Lac substitution (vanA/B/C genes)
Aminoglycosides	Irreversible 30S ribosome binding; mistranslation induction	Gentamicin, Amikacin, Tobramycin	Aminoglycoside-modifying enzymes, 16S rRNA methylation
Fluoroquinolones	DNA gyrase (gyrA) & topoisomerase IV (parC) inhibition	Ciprofloxacin, Levofloxacin, Moxifloxacin	Target mutations, efflux pumps, QRDR alterations
Macrolides	50S ribosome (23S rRNA) binding; protein synthesis blockade	Azithromycin, Erythromycin, Clarithromycin	Erm methylases, MFS efflux, esterase inactivation
Tetracyclines	30S ribosome binding; tRNA-aminoacyl complex blockade	Doxycycline, Tigecycline, Minocycline	Tet efflux pumps, ribosomal protection proteins
Polymyxins	Disruption of Gram-negative outer membrane via LPS binding	Colistin (Polymyxin E), Polymyxin B	LPS modification (mcr-1 gene), outer membrane remodeling
Oxazolidinones	50S ribosome binding; inhibition of initiator fMet-tRNA positioning	Linezolid, Tedizolid	23S rRNA mutations (G2576T), cfr methyltransferase

Resistance mechanisms correspondingly target whichever of these molecular interactions the antibiotic depends upon. The following subsections delineate each principal resistance strategy.

3.1 Enzymatic Drug Inactivation: β-Lactamases and Beyond



Figure 2. Enzymatic degradation by β-lactamases: hydrolysis of the β-lactam ring rendering antibiotics inactive.

Enzymatic inactivation represents the dominant resistance mechanism against the most widely deployed antibiotic class—the β-lactams. β-Lactamases accomplish this through hydrolysis of the highly strained four-membered β-lactam ring, the pharmacophoric core shared by penicillins, cephalosporins, monobactams, and carbapenems, producing pharmacologically inert ring-opened products incapable of binding their penicillin-binding protein (PBP) targets [20]. The clinical consequence is immediate and devastating: a compound designed to inhibit bacterial cell wall crosslinking is disarmed before it reaches its target. Structurally, β-lactamases are classified into four molecular classes (A–D), distinguished by their catalytic architecture and substrate specificity (Table 1). Classes A, C, and D employ a serine-based nucleophilic mechanism, while Class B enzymes—the metallo-β-lactamases (MBLs)—depend on zinc ion coordination for catalytic activity and exhibit the broadest substrate range, encompassing all β-lactams except monobactams [21].

Table 1. Molecular Classification of β-Lactamases: Structural Features, Key Enzymes, and Inhibitor Susceptibility

Class	Functional Group	Key Enzymes	Organisms	β-Lactamase Inhibitor Susceptibility
A	2a–2f, 2be	TEM, SHV, CTX-M, KPC	Gram+ & Gram−	Susceptible (except KPC)
B (MBL)	3a, 3b, 3c	NDM-1, VIM, IMP	Gram−	Resistant; EDTA chelation
C	1	AmpC, CMY, FOX, DHA	Gram−	Resistant to standard inhibitors
D	2d	OXA-type enzymes	Gram−; Acinetobacter	Partial (clavulanate, tazobactam)

Among Class A enzymes, ESBLs—particularly CTX-M variants, which have become globally dominant since the 1990s—confer resistance to third- and fourth-generation cephalosporins and are frequently co-encoded on plasmids carrying aminoglycoside, quinolone, and sulfonamide resistance determinants, precipitating multidrug-resistant phenotypes from a single plasmid

acquisition event [22]. Klebsiella pneumoniae carbapenemases (KPCs), also Class A enzymes, represent a further escalation, hydrolysing virtually all β-lactam drugs including carbapenems—traditionally the antibiotics of last resort for Gram-negative infections—while retaining partial susceptibility to ESBL inhibitors such as avibactam [23]. Class B MBLs, exemplified by NDM-1, VIM, and IMP types, are of particular therapeutic concern because they hydrolyse carbapenems with high efficiency and are entirely refractory to all currently approved β-lactamase inhibitors. NDM-1, first characterised from a patient repatriated from New Delhi in 2009, has since disseminated globally on highly promiscuous conjugative plasmids, appearing in Enterobacteriaceae, Acinetobacter, and Pseudomonas across six continents [24]. Infections caused by NDR-1-producing strains carry in-hospital mortality rates approaching 50–70%, underscoring the severity of the clinical challenge they represent. Beyond β-lactamases, enzymatic inactivation of aminoglycosides through acetyltransferases, phosphotransferases, and nucleotidyltransferases constitutes another clinically significant resistance category. Similarly, chloramphenicol acetyltransferases and macrolide esterases represent enzymatic resistance strategies deployed across distinct antibiotic classes, collectively illustrating the chemical versatility of bacterial enzymatic defences [25].

3.2 Drug Target Modification



Figure 3. Mechanism of antimicrobial resistance through target site alteration, comparing susceptible and resistant bacteria.

A second major resistance strategy involves structural alteration of the antibiotic's molecular target such that drug binding affinity is substantially reduced while the target retains its essential biological function. This mechanism is exemplified with particular clarity in methicillin-resistant Staphylococcus aureus (MRSA), wherein acquisition of the mecA gene encodes PBP2a—a modified penicillin-binding protein with markedly reduced affinity for virtually all β-lactam antibiotics—conferring resistance to the entire β-lactam class through a single gene acquisition event [26]. In Enterococcus faecium and E. faecalis, vancomycin resistance results from reprogramming of peptidoglycan precursor termini from D-alanyl-D-alanine to D-alanyl-D-lactate (vanA/vanB clusters) or D-alanyl-D-serine (vanC cluster), reducing vancomycin's binding affinity by approximately 1,000-fold while preserving peptidoglycan biosynthesis [27]. The

vanA gene cluster, borne on transferable transposons, has been documented to transfer between enterococcal and staphylococcal species, generating vancomycin-intermediate and vancomycin-resistant S. aureus (VISA/VRSA) strains of profound therapeutic concern. Fluoroquinolone resistance most commonly arises through point mutations in the quinolone resistance-determining regions (QRDRs) of gyrA and parC genes, encoding subunits of DNA gyrase and topoisomerase IV, respectively. These mutations sterically impede quinolone-enzyme-DNA ternary complex formation without ablating the enzyme's capacity to resolve topological supercoils during replication [28]. Ribosomal target modification—including 23S rRNA methylation by Erm methyltransferases conferring cross-resistance to macrolides, lincosamides, and streptogramins B (MLSB phenotype)—further exemplifies how single target modifications can generate broad clinical resistance phenotypes [29].

3.3 Efflux Pump-Mediated Drug Extrusion



Figure 4. Efflux pump families and their role in active antimicrobial drug extrusion in resistant bacteria.

Active drug efflux constitutes an evolutionarily ancient resistance strategy predating the antibiotic era, reflecting the primordial physiological role of membrane transporters in exporting cytotoxic metabolites and maintaining chemical homeostasis within the bacterial cell. Five structurally and mechanistically distinct efflux pump superfamilies have been characterised in clinically relevant pathogens: the resistance-nodulation-division (RND) family, major facilitator superfamily (MFS), small multidrug resistance (SMR) family, multidrug and toxin extrusion (MATE) family, and ATP-binding cassette (ABC) transporters [30]. RND-type efflux systems, exemplified by AcrAB-TolC in E. coli and MexAB-OprM in P. aeruginosa, are tripartite systems spanning the inner membrane, periplasm, and outer membrane, capable of extruding structurally diverse substrates including β-lactams, fluoroquinolones, tetracyclines, macrolides, and even bile salts and detergents [31]. Their broad substrate promiscuity means that constitutive overexpression—typically driven by mutations in regulatory genes such as marR, acrR, or mexR—simultaneously generates resistance to multiple antibiotic classes in a single mutational step, a phenomenon with profound implications for empiric therapy selection. Acinetobacter

baumannii is notable for the density and diversity of its efflux pump repertoire, carrying genes from the RND, MFS, MATE, SMR, and PACE families simultaneously, contributing to the clinically devastating pan-drug-resistant phenotypes increasingly reported in healthcare settings globally [32]. Efflux pump inhibitors (EPIs) represent a rational therapeutic counterstrategy: compounds such as phenylalanine-arginyl-β-naphthylamide (PAβN), a peptidomimetic RND inhibitor, and MP-601205, a structural derivative, have demonstrated in vitro efficacy in resensitising resistant strains to fluoroquinolones and β-lactams [33]. However, none has achieved clinical approval, with toxicity, poor pharmacokinetics, and inadequate in vivo efficacy constituting the principal obstacles to clinical translation.

3.4 Reduced Intracellular Drug Accumulation through Porin Downregulation

In Gram-negative bacteria, which possess an outer membrane as a physical barrier to hydrophilic antimicrobials, selective downregulation or structural modification of outer membrane porins (OMPs) provides an additional mechanism to reduce intracellular antibiotic accumulation. OprD in P. aeruginosa is the principal channel mediating imipenem uptake; mutational loss or transcriptional suppression of OprD reduces imipenem susceptibility by 4- to 16-fold, frequently in concert with MexCD-OprJ or MexXY-OprM upregulation to produce high-level carbapenem resistance without carbapenemase gene acquisition [34]. In K. pneumoniae, deletion or reduced expression of outer membrane proteins OmpK35 and OmpK36—functionally homologous to E. coli OmpF and OmpC—elevates MICs for cephalosporins and carbapenems substantially, particularly when combined with ESBL or AmpC production on the same genetic background. This mechanistic synergy between enzymatic resistance and reduced permeability represents a potent combinatorial phenotype that profoundly limits therapeutic options [35].

3.5 Biofilm Formation and Its Contribution to Clinical Resistance



Figure 5. Stages of biofilm formation and mechanisms by which biofilms contribute to antimicrobial resistance.

Biofilms—structured polymicrobial communities encased within a self-produced extracellular polymeric substance (EPS) matrix adherent to biotic or abiotic surfaces—represent a fundamentally distinct mode of bacterial existence that confers resistance phenotypes 10- to 1,000-fold higher than their planktonic counterparts, through mechanisms that are both passive and active [36]. Biofilm-embedded bacteria are implicated in approximately 65% of all nosocomial infections and 80% of chronic infections, including those associated with indwelling medical devices, chronic wounds, cystic fibrosis lung infections, and prosthetic joint infections [37]. The EPS matrix, composed of exopolysaccharides (e.g., alginate, Pel, Psl in P. aeruginosa), extracellular DNA (eDNA), lipopolysaccharide, and proteins, functions as a physical diffusion barrier that retards antibiotic penetration, inactivates certain antibiotics through chemical sequestration, and maintains local pH gradients that diminish aminoglycoside activity [38]. Beyond the physical barrier, biofilm-associated bacteria exhibit phenotypic plasticity characterised by markedly reduced metabolic activity and growth rates, rendering them largely insensitive to antibiotics whose bactericidal activity is growth-dependent, including β-lactams and fluoroquinolones. A small subpopulation of dormant "persister cells" within biofilms maintains viable but non-growing status, surviving antibiotic exposure and serving as a reservoir for biofilm recrudescence upon antibiotic withdrawal [39]. Quorum sensing (QS) signalling networks—mediated by N-acyl homoserine lactones (AHLs), autoinducer-2 (AI-2), and Pseudomonas quinolone signal (PQS) in Gram-negative species—regulate biofilm maturation, EPS synthesis, and the transition between planktonic and sessile states in a cell density-dependent manner. QS inhibition has accordingly emerged as a rational anti-biofilm strategy, with compounds targeting LasR, RhlR, and PqsR receptors demonstrating biofilm disruption activity in preclinical models, though clinical validation remains elusive [40].

Table 2. Summary of Principal AMR Mechanisms, Molecular Bases, Relevant Pathogens, and Clinical Consequences

Resistance Mechanism	Molecular Basis	Representative Pathogens	Clinical Significance
Enzymatic Degradation	β-lactamase, carbapenemase production; ring hydrolysis	K. pneumoniae, E. coli, P. aeruginosa	Failure of β-lactam therapies; pandemic MDR spread
Target Site Alteration	PBP mutation (PBP2a), rRNA methylation, gyrA/parC mutations	MRSA, VRE, MDR-TB, Enterococci	Broad antibiotic class failure including carbapenems
Efflux Pump Overexpression	RND, MFS, MATE, SMR, ABC families extrude drugs	A. baumannii, P. aeruginosa, E. coli	Multidrug resistance; synergistic with other mechanisms
Reduced Permeability	Porin loss (OprD, OmpF, OmpK35/36), membrane remodeling	K. pneumoniae, A. baumannii	Carbapenem resistance without carbapenemase genes
Biofilm Formation	EPS matrix, quorum sensing, dormant persister cells	P. aeruginosa, S. aureus, E. faecalis	Chronic refractory infections; device-associated infections
Horizontal Gene Transfer	Conjugative plasmids, transposons, integrons, phage transduction	Enterobacteriaceae, Staphylococci	Rapid inter-species ARG dissemination globally

4. Evolution of Antimicrobial Resistance

4.1 Genetic Mutation and Selective Pressure



Figure 6. Evolution of antimicrobial resistance through genetic mutations, horizontal gene transfer, and evolutionary dynamics.

Darwinian natural selection operating on spontaneous genetic mutations provides the fundamental evolutionary engine driving AMR emergence within bacterial populations. During exponential growth, error-prone DNA polymerases, UV radiation, reactive oxygen species, and the SOS response to DNA damage collectively generate nucleotide substitutions, insertions, and deletions at background rates of approximately 10^{-9} to 10^{-10} mutations per base pair per replication cycle [41]. While the vast majority of mutations are neutral or deleterious, those conferring even a marginal survival advantage under antibiotic exposure are powerfully selected, expanding from rare variants to dominant clones within remarkably few generations. The concept of the "mutant selection window" (MSW)—the range of antibiotic concentrations above the MIC of wild-type bacteria but below the mutant prevention concentration (MPC) necessary to suppress resistant mutant proliferation—is pivotal for understanding how sub-therapeutic antibiotic concentrations in clinical and agricultural settings selectively amplify resistant subpopulations [42]. Crucially, antibiotic exposure below the MPC but above the MIC enriches for first-step mutants, which may subsequently acquire additional mutations conferring progressively higher-level resistance through an iterative stepwise accumulation process well-documented in Mycobacterium tuberculosis and Helicobacter pylori resistance evolution [43]. Hypermutable strains—characterised by mutations in mismatch repair (MMR) genes such as mutS, mutL, and mutU—exhibit mutation rates 100- to 1,000-fold above baseline and are disproportionately recovered from chronic infections, antibiotic-treated populations, and biofilm environments where oxidative stress and the SOS response are constitutively activated [44]. These "mutator" phenotypes accelerate resistance evolution and have been documented in clinical P. aeruginosa isolates from cystic fibrosis patients, where chronic antibiotic exposure creates strong directional selection for hypermutability.

4.2 Horizontal Gene Transfer: Conjugation, Transformation, and Transduction

While vertical inheritance of mutational resistance is significant, the principal mechanism driving AMR dissemination at both population and species levels is horizontal gene transfer (HGT)—the lateral movement of genetic material between bacterial cells independent of reproduction [45]. HGT enables bacteria to acquire complex, multi-gene resistance determinants in a single event, bypassing the evolutionary time required for stepwise mutational accumulation, and explains the explosive inter-continental spread of specific ARGs such as bla-NDM-1, bla-KPC, and mcr-1 within clinically compressed timeframes. Conjugation, the most epidemiologically significant HGT pathway, involves direct cell-to-cell contact mediated by a type IV secretion system (T4SS) encoded on conjugative plasmids or integrative and conjugative elements (ICEs), enabling unidirectional transfer of plasmid DNA from donor to recipient [46]. Conjugative plasmids often carry multiple resistance determinants co-localised within resistance islands, transposons, or integrons, facilitating simultaneous acquisition of resistance to multiple antibiotic classes through a single conjugative event. The promiscuity of certain IncF and IncI plasmid incompatibility groups across Gram-negative Enterobacteriaceae species—including E. coli, K. pneumoniae, Salmonella, and Shigella—has enabled global dissemination of CTX-M ESBLs and carbapenemases within interconnected healthcare and community reservoirs [47]. Transformation, the uptake and chromosomal integration of naked environmental DNA, operates in naturally competent species including Streptococcus pneumoniae and Haemophilus influenzae, contributing to mosaic penicillin-binding protein gene evolution responsible for β-lactam resistance in these pneumococcal pathogens [48]. Bacteriophage-mediated transduction facilitates ARG transfer via phage-packaged bacterial DNA fragments, with particular relevance in S. aureus pathogenicity island mobilisation and in antimicrobial-treated host environments where SOS-induced phage induction enhances transduction frequency [49].

4.3 Mobile Genetic Elements as Resistance Vectors

Mobile genetic elements (MGEs)—including plasmids, transposons, insertion sequences, and integrons—function as both repositories and vectors for ARGs, amplifying the efficiency of HGT-mediated resistance dissemination. Integrons, in particular, serve as natural gene expression platforms capable of sequentially capturing gene cassettes encoding resistance to structurally unrelated antibiotics through site-specific recombination mediated by an integrase enzyme encoded within the integron [50]. Class 1 integrons are extraordinarily prevalent in clinical Gram-negative isolates worldwide, frequently associated with sul1-encoded sulfonamide resistance and often embedded within composite transposons that facilitate integration into conjugative plasmids or the bacterial chromosome. The phenomenon of co-resistance and co-selection further complicates AMR management: genes conferring resistance to biocides, heavy metals, and disinfectants are frequently co-located on plasmids or integrons with ARGs, meaning that selection pressure from non-antibiotic environmental contaminants—including mercury, zinc, copper, and quaternary ammonium compounds—may inadvertently co-select for antibiotic resistance in microbial communities exposed to agricultural or industrial effluents [51].

4.4 Evolutionary Dynamics and the Fitness Cost of Resistance

The persistence of AMR in bacterial populations despite the thermodynamic disadvantage imposed by resistance gene expression—which diverts

metabolic resources away from replication—reflects the operation of complex evolutionary dynamics beyond simple Darwinian selection [52]. Resistance determinants that initially impose significant fitness costs may undergo compensatory mutations in secondary loci that restore growth rates without eliminating resistance, effectively "locking in" resistance genotypes even in the absence of continued antibiotic selection pressure [53]. This compensatory evolution phenomenon has been experimentally demonstrated for fluoroquinolone-resistant E. coli, rifampicin-resistant M. tuberculosis, and tetracycline-resistant S. pneumoniae, and helps explain the persistence of resistance in antibiotic-naive clinical isolates collected after antibiotic cycling interventions. Population dynamics modelling incorporating stochastic demographic fluctuations, environmental variability, and the public goods nature of certain resistance mechanisms (e.g., β-lactamase secretion in biofilms benefiting neighbouring susceptible cells through periplasmic drug inactivation) reveals that AMR persistence is substantially more robust than deterministic models predict [54]. This insight has important implications for de-escalation stewardship strategies, which may be less effective than anticipated in contexts of high initial resistance prevalence.

5. Clinical Impact of Antimicrobial Resistance

5.1 Global Mortality and Morbidity Burden



Figure 7. Clinical impact of antimicrobial resistance: increased morbidity, mortality, and economic burden.

The clinical consequences of AMR extend far beyond individual therapeutic failure, encompassing systemic healthcare system strain, economic destabilisation, and threats to the viability of cornerstone medical interventions. The GRAM 2022 analysis quantified 1.27 million deaths directly attributable to bacterial AMR in 2019, with sub-Saharan Africa and South Asia disproportionately affected owing to high infectious disease burden, limited diagnostic infrastructure, and inadequate access to second- and third-line antibiotics [5]. Resistant strains of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii collectively accounted for the majority of attributable deaths, with carbapenem-resistant pathogens representing the highest-mortality phenotypes. AMR-related infections are associated with hospital length of stay extending by an average of 6–13 days compared with susceptible infections, with

attributable mortality risks 2- to 3-fold greater for MDR versus susceptible infections in critical care settings [55]. Surgical site infections caused by MRSA carry case fatality rates approaching 20–25% in immunocompromised patients, while bloodstream infections caused by CRE organisms exhibit crude in-hospital mortality of 40–70% in multiple prospective cohort studies from Europe and North America [56]. Table 5 summarises the AMR burden by principal pathogen, contextualised within the WHO ESKAPE pathogen framework—an acronym (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacterales) designating the six pathogen taxa responsible for the predominance of nosocomial MDR infections globally.

Table 5. AMR Burden by ESKAPE Pathogen: Resistance Profile, Global Deaths, Available Last-Line Agents, and WHO Priority Classification

Pathogen (ESKAPE)	Key Resistance Profile	Global Attributable Deaths (2019)	Preferred Last-Line Agents	WHO Priority Tier
Enterococcus faecium	Vancomycin-resistant (VRE); linezolid resistance emerging	~50,000 annually	Daptomycin, Tedizolid	High
Staphylococcus aureus (MRSA)	Methicillin-resistant; VISA/VRSA strains emerging	~120,000 directly	Vancomycin, Daptomycin, Ceftaroline	High
Klebsiella pneumoniae	KPC, NDM-1 carbapenemase; hypervirulent strains	~150,000 directly	Ceftazidime-avibactam, Colistin	Critical
Acinetobacter baumannii	Pan-resistant; XDR carbapenem-resistant strains	~60,000 annually	Colistin + Rifampicin; new sulbactam-durlobactam	Critical
Pseudomonas aeruginosa	MDR; MexXY efflux + OprD loss + MBLs	~80,000 annually	Ceftolozane-tazobactam; Imipenem-cilastatin-relebactam	Critical
Enterobacteriaceae (CRE)	Carbapenem-resistant; ESBL producers	~210,000 directly	Ceftazidime-avibactam; Meropenem-vaborbactam	Critical

5.2 Impact on Medical and Surgical Procedures

Perhaps the most underappreciated dimension of the AMR crisis is the existential threat it poses to the safety of routine and complex medical and surgical procedures that are entirely dependent on effective prophylactic and therapeutic antibiotics. Cancer chemotherapy, organ transplantation, prosthetic joint replacement, cardiac surgery, and neonatal intensive care rely implicitly on the availability of reliable antibiotics to manage procedural infection risk [57]. Modelling studies project that if current antibiotic efficacy levels deteriorate substantially, infection-related mortality following common surgical procedures could increase 2- to 10-fold, and long-term cancer survival rates following chemotherapy could decline by 15–20% owing to unmanageable infectious complications [58]. The clinical burden of healthcare-associated infections (HAIs) attributable to MDR organisms is already substantial. Ventilator-associated pneumonia caused by XDR Acinetobacter baumannii or P. aeruginosa carries attributable mortality exceeding 40% in high-dependency units, while central line-associated bloodstream infections (CLABSIs)

caused by carbapenem-resistant Enterobacteriaceae impose treatment durations extending by months and costs escalating by tens of thousands of dollars per episode relative to susceptible infections [59].

5.3 Economic Burden

The economic consequences of AMR are multidimensional, encompassing direct costs (prolonged hospitalisation, costly last-resort antibiotic regimens, enhanced isolation and barrier nursing requirements, repeated diagnostic workup), indirect costs (productivity losses from premature mortality and prolonged morbidity), and systemic costs (diminished investor confidence in antibiotic R&D, healthcare system destabilisation). Conservative estimates from the World Bank project that AMR-related GDP losses could reach 1.1% annually in high-income countries and 3.8% in low-income countries by 2050, with cumulative global losses potentially exceeding USD 100 trillion over the same period [60]. These macroeconomic projections fail, however, to capture the broader societal cost of AMR-driven retrenchment of the medical advances achieved during the antibiotic era—the effective reversal of which would represent a public health catastrophe without modern historical precedent.

6. Therapeutic Challenges and Current Antibiotic Pipeline

6.1 The Dwindling Antibiotic Pipeline

The antibiotic drug development pipeline has experienced progressive atrophy over the past four decades, with most major pharmaceutical corporations withdrawing from antibiotic research programmes owing to unfavourable economic models: antibiotics prescribed for short-course acute infections generate substantially lower revenues than chronic disease medications, while the ever-present threat of resistance emergence rapidly erodes any novel antibiotic's commercial value [61]. A WHO 2023 analysis of the clinical pipeline identified 27 antibiotics in clinical development—of which fewer than half represented truly novel chemical classes or targets—contrasted with a roster of 50–60 antibiotic candidates in early clinical development during the 1990s peak [7]. Of the antibiotics approved by the FDA and EMA since 2017, the majority represent modifications of established structural scaffolds (cephalosporins, tetracyclines, β-lactam-inhibitor combinations) designed to circumvent specific resistance mechanisms rather than engage fundamentally novel targets. While clinically valuable agents such as ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, and omadacycline have meaningfully expanded treatment options for specific MDR pathogens, their susceptibility to emerging resistance—already documented for avibactam combinations within 2–3 years of approval—highlights the fragility of the therapeutic gains achieved [62].

6.2 MDR Pathogens and the Last-Resort Antibiotic Problem

The emergence of extensively drug-resistant (XDR) and pan-drug-resistant (PDR) organisms—defined as susceptibility to one or two antibiotic classes, and no approved antibiotic classes, respectively—has created clinical scenarios where the physician's pharmacological toolkit is effectively empty. PDR A. baumannii infections, increasingly reported in conflict zones, long-term care facilities, and transplant centres, represent the current nadir of the antibiotic era, with patients managed using antibiotics whose toxicity profiles (colistin nephrotoxicity) are considered acceptable only in the context of otherwise uniformly fatal

infections [63]. MDR M. tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) present a distinct but equally urgent therapeutic challenge, requiring treatment regimens extending 18–24 months with multiple agents associated with significant toxicity, poor tolerability, and high rates of treatment abandonment. The 2023 WHO Global TB Report documented 410,000 new MDR/RR-TB cases annually, with treatment success rates for XDR-TB below 50% in most high-burden settings [64].

6.3 Diagnostic Limitations

The management of AMR infections is critically dependent on rapid, accurate pathogen identification and susceptibility testing, yet the current diagnostic standard—culture-based AST requiring 24–72 hours—substantially delays targeted therapy, perpetuating empiric broad-spectrum antibiotic use those further drives resistance selection [65]. Rapid molecular diagnostics including multiplex PCR panels, loop-mediated isothermal amplification (LAMP), and whole-genome sequencing (WGS)-based resistance gene characterisation offer transformative potential, but their implementation is constrained by cost, technical complexity, and the requirement for positive culture prior to molecular testing in many platforms. Phenotypic rapid AST platforms—including microfluidic broth microdilution, dark-field microscopy-based growth detection, and mass spectrometry-based MIC determination—are achieving results within 3–6 hours in academic centres, but clinical validation across diverse pathogen species, resistance phenotypes, and complex specimen matrices is incomplete, and regulatory approval has lagged behind technical development [66].

7. Emerging Strategies to Combat Antimicrobial Resistance



Figure 8. Multi-pronged strategies to combat antimicrobial resistance, including novel therapeutics, phage therapy, CRISPR, and stewardship.

The gravity of the AMR crisis has stimulated unprecedented scientific innovation across diverse therapeutic modalities. Table 4 summarises the principal emerging strategies currently under investigation, with notes on mechanistic basis, clinical development status, and outstanding challenges.

Table 4. Emerging Therapeutic Strategies Against MDR Infections: Mechanism, Development Status, and Translational Challenges

Strategy	Mechanism	Current Status	Challenges & Limitations
Phage Therapy	Lytic bacteriophages selectively target and lyse resistant bacteria; phage cocktails prevent resistance evolution	Compassionate use; Phase I/II clinical trials; FDA Expanded Access	Narrow host range; phage resistance; regulatory hurdles; manufacturing scalability
Antimicrobial Peptides (AMPs)	Membrane disruption via electrostatic interaction; immunomodulation; anti-biofilm activity	Multiple preclinical candidates; few Phase I–III trials (defensins, LL-37 derivatives)	Cytotoxicity; hemolytic activity; stability issues; high production costs
CRISPR-Cas Antimicrobials	Sequence-specific ARG disruption; resensitisation of MDR strains; precise killing of pathogens	Proof-of-concept and preclinical; phage-delivered CRISPR systems under evaluation	Delivery efficiency in vivo; off-target effects; phage-CRISPR interactions
β-Lactamase Inhibitors	Suicide inhibitor or non-β-lactam inhibitor (avibactam, relebactam) restores β-lactam activity	FDA-approved combinations: ceftazidime-avibactam, meropenem-vaborbactam	Class B (MBL) largely unaddressed; emerging resistance to inhibitor combinations
Antivirulence Agents	Target virulence factors (quorum sensing, toxin secretion) without antibiotic pressure	Preclinical; some Phase I trials (LasR inhibitors, Pel/Psl biofilm inhibitors)	Resistance still possible; reduced direct killing; adjunctive only
Nanoparticle Drug Delivery	Enhanced penetration of biofilms; targeted drug release; silver/zinc nanoparticle intrinsic antimicrobial action	Preclinical; early Phase I–II trials for wound and lung infections	Toxicity profiles; regulatory pathway; formulation stability; manufacturing cost
AI-Driven Drug Discovery	Machine learning screens novel scaffolds; predicts resistance mutation trajectories; optimizes pharmacophores	Halicin and abaucin discovered by deep learning; several candidates in preclinical validation	Interpretability; data quality dependence; translational gap from in silico to in vivo

7.1 Phage Therapy

Bacteriophage therapy—the therapeutic application of viruses that infect and lyse bacteria with high host specificity—has undergone a renaissance of scientific and clinical interest following a century of relative neglect in Western medicine since the advent of antibiotics [67]. The mechanistic attractions of phage therapy are considerable: phages are inherently self-amplifying at the site of infection, exhibit strain-level specificity that spares the host microbiome, penetrate biofilm matrices through enzymatic EPS degradation by phage-encoded depolymerases, and engage resistance mechanisms distinct from those exploited by conventional antibiotics, thereby retaining activity against many MDR organisms [68]. Contemporary phage therapy clinical experience, though largely restricted to compassionate-use cases and early-phase trials, encompasses successful treatment of refractory MRSA bacteraemia, prosthetic joint infections

caused by MDR P. aeruginosa, and XDR A. baumannii pulmonary infections in mechanically ventilated patients [69]. Phage cocktails—mixtures of multiple phages targeting distinct bacterial surface receptors—are preferred clinically to minimise the probability of rapid phage resistance emergence and broaden host range coverage. The WHO Regional Office for Europe's 2025 evidence synthesis on bacteriophage therapy concluded that sufficient safety and early-phase efficacy data now exist to support randomised controlled trial evaluation, signalling a potential inflection point in the regulatory trajectory [70].

7.2 Antimicrobial Peptides (AMPs)

Antimicrobial peptides—short, cationic, amphipathic molecules of 15–50 amino acid residues produced by virtually all multicellular organisms as components of innate immune defence—offer mechanistic diversity that conventional antibiotics cannot replicate [71]. AMPs achieve bactericidal activity through electrostatic attraction to the negatively charged bacterial membrane surface, followed by membrane intercalation and pore formation, membrane disruption, and in some cases translocation to intracellular targets including DNA, ribosomes, and cell wall biosynthesis machinery. The multiplicity of membrane and intracellular targets engaged simultaneously renders development of high-level AMP resistance energetically costly and evolutionary constrained, as the alterations necessary to reduce AMP activity (e.g., membrane phosphatidylglycerol substitution with lysyl-phosphatidylglycerol) impose substantial fitness costs on bacterial growth and pathogenicity [72]. Synthetic AMP derivatives and peptidomimetics engineered to improve proteolytic stability, reduce hemolytic toxicity, and enhance bioavailability are advancing through preclinical development, with several compounds including LL-37 analogues, defensin mimetics, and cyclic lipopeptides demonstrating potent in vivo efficacy against MRSA and MDR Gram-negative infections in murine models [73]. Synergistic combinations of AMPs with conventional antibiotics—exploiting AMP-mediated membrane permeabilisation to enhance intracellular antibiotic accumulation—represent a particularly promising combinatorial strategy with significant clinical development potential.

7.3 CRISPR-Cas-Based Antimicrobials

CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein) systems, naturally functioning as bacterial adaptive immune mechanisms against invading phages and MGEs, are being repurposed as precision antimicrobial tools capable of selectively targeting and eliminating specific resistance genes, virulence determinants, or entire bacterial species with single-nucleotide specificity [74]. In the antimicrobial application, guide RNAs (gRNAs) engineered to recognise ARG sequences within target bacterial genomes direct the Cas9 or Cas12 nuclease to introduce lethal double-stranded chromosomal breaks, selectively killing bacteria harbouring the target gene while sparing non-target species—a precision killing capability entirely beyond conventional antibiotics [75]. CRISPR-based strategies also offer the possibility of ARG "resensitisation"—the targeted deletion of resistance genes from MDR organisms to restore antibiotic susceptibility—and sequence-specific elimination of hypervirulent or carbapenem-resistant clones from complex polymicrobial infections. Delivery of CRISPR-Cas components to target bacteria in vivo presents the principal technical obstacle; phage-based delivery vehicles, lipid nanoparticle encapsulation, and conjugative

plasmid transfer are the leading platforms under investigation [76].

7.4 Antimicrobial Stewardship Programs

Antimicrobial stewardship programs (ASPs) represent the most immediately implementable intervention within existing healthcare infrastructure, aiming to optimise the selection, dose, route, and duration of antibiotic therapy to achieve clinical cure while minimising collateral selective pressure on the indigenous microbiome and institutional resistance ecology [77]. Prospective audit and feedback, formulary restriction, pre-authorisation requirements for broad-spectrum agents, rapid diagnostic integration, and pharmacist-led de-escalation are core ASP components with robust evidence bases from systematic reviews demonstrating 20–35% reductions in antibiotic consumption and 10–25% reductions in Clostridioides difficile infection rates [78]. A compelling limitation of hospital-centric ASPs, however, is that community antibiotic use—which accounts for 60–80% of total human antibiotic consumption in high-income countries and substantially more in LMICs—falls largely outside their purview. Community-level stewardship interventions, including delayed prescribing strategies, public education campaigns, point-of-care diagnostic facilitation, and prescriber academic detailing, are increasingly recognised as essential complements to hospital programmes but require sustained political will and public health infrastructure investment [79].

7.5 Infection Prevention and Control

Reducing the transmission of resistant organisms within healthcare settings is a cornerstone of AMR management, complementing stewardship by limiting the amplification and spread of resistant strains that antibiotic selection pressure has generated. Standard and transmission-based precautions—contact precautions for patients colonised or infected with MDR organisms, rigorous hand hygiene with alcohol-based hand rubs, environmental decontamination, and active microbiological surveillance through screening swabs at high-risk admission points—collectively interrupt nosocomial MDR transmission chains [80]. Care bundles targeting the specific risk factors for common HAI types—central-line insertion checklists, ventilator-associated pneumonia prevention protocols, surgical site infection surveillance—have demonstrated 30–70% reductions in targeted infection rates in multicenter implementation studies, with health-economic analyses consistently demonstrating favourable cost-effectiveness ratios [81]. In the One Health context, infection prevention intersects with animal husbandry biosecurity, environmental waste management, and food safety regulation, underscoring that AMR containment demands coordinated action across human, animal, and environmental health sectors simultaneously.

7.6 Artificial Intelligence and Genomics in AMR Management

The convergence of artificial intelligence and genomic technologies with clinical microbiology is generating transformative tools for AMR surveillance, resistance prediction, and novel drug discovery. Machine learning algorithms trained on whole-genome sequence data can predict antibiotic susceptibility phenotypes for M. tuberculosis with accuracies exceeding 95%, and for Gram-negative pathogens with sensitivities and specificities sufficient to guide clinical prescribing decisions within hours of colony isolation [82]. Deep learning models applied to structural databases of known antimicrobial compounds have identified novel scaffolds with activity against MDR pathogens, including the

discovery of halicin—a structurally novel antibiotic with potent activity against C. difficile, A. baumannii, and M. tuberculosis—and abaucin, the first narrow-spectrum antibiotic with selective activity against A. baumannii, both identified through neural network screening of chemical libraries comprising millions of compounds [83]. Population genomics platforms integrating WGS data from clinical, veterinary, environmental, and food surveillance streams within a One Health framework are providing unprecedented resolution of AMR transmission networks, identifying cryptic reservoirs, quantifying inter-sectoral gene flow, and enabling attribution of specific resistance clusters to geographic, temporal, and ecological sources [84]. As sequencing costs continue to decline, real-time genomic surveillance integrated into clinical decision support systems will progressively transform AMR epidemiology from a retrospective descriptive discipline to a prospective, actionable, precision public health tool.

8. Future Perspectives

The future trajectory of AMR management will be shaped by the capacity of the scientific, clinical, and policy communities to translate mechanistic insights into durable clinical interventions, while simultaneously addressing the structural socioeconomic determinants—antibiotic access inequity, inadequate healthcare infrastructure in LMICs, and misaligned pharmaceutical market incentives—that sustain the global resistance burden. The personalised medicine paradigm, applied to infectious diseases, envisions treatment strategies individualised to the pathogen's precise genomic resistance profile, the host's immune and pharmacogenomic characteristics, and the ecological context of infection. Rapid WGS-guided therapy selection, biomarker-informed treatment duration decisions, and phage cocktails tailored to individual isolate receptor profiles represent near-future clinical capabilities whose systematic implementation will require significant investment in laboratory infrastructure and health professional training [85]. Push and pull market incentive mechanisms—including transferable exclusivity vouchers, subscription-based payment models decoupled from antibiotic sales volumes, and direct public investment in antibiotic clinical development—are gaining policy traction in major pharmaceutical markets and represent plausible structural reforms capable of restoring commercial viability to antibiotic development without compromising access in LMICs [86]. The CARB-X, GARDP, and AMR Action Fund public-private partnership models demonstrate that coordinated international co-investment can meaningfully accelerate early-stage antibiotic development, though the translational pipeline from early-phase candidate to approved antibiotic remains lengthy and attrition-prone. Ultimately, the AMR crisis resists resolution through any single intervention, however technically elegant. A sustainable response demands simultaneous progress across the full spectrum of determinants: reducing antimicrobial selection pressure through stewardship and infection prevention, replenishing the antibiotic pipeline through innovation and appropriate market incentives, harnessing emerging technologies to transcend conventional antibiotic limitations, and strengthening the global health equity frameworks that determine whether effective interventions reach the populations most severely affected by resistance-related mortality. The intersection of genomics, artificial intelligence, molecular biology, pharmacology, and public health policy defines the arena in which the battle against antimicrobial resistance will ultimately be won or lost.

CONCLUSION

Antimicrobial resistance represents one of the most complex and consequential threats to global public health in the modern era, arising from the convergence of molecular biological mechanisms—enzymatic drug inactivation, target modification, active efflux, reduced permeability, and biofilm formation—with evolutionary processes of mutation and horizontal gene transfer operating under intense anthropogenic selective pressure. The clinical and economic toll of resistance is already devastating and will intensify dramatically in the absence of immediate, coordinated, and sustained global action. This review has delineated the principal biochemical mechanisms underlying AMR across major pathogen classes, contextualised the evolutionary forces driving ARG dissemination through mobile genetic elements and horizontal gene transfer, quantified the substantial clinical burden of resistance-related mortality and procedural compromise, and surveyed the landscape of emerging therapeutic countermeasures—from phage therapy and antimicrobial peptides to CRISPR-based antimicrobials and AI-guided drug discovery. Each of these modalities offers genuine promise; none offers a comprehensive solution in isolation. The most defensible near-term strategy integrates robust antimicrobial stewardship with enhanced infection prevention and control, underpinned by rapid diagnostic capability and real-time genomic surveillance, while investing long-term in the fundamental scientific advances—novel targets, resistance-evading chemical scaffolds, and biological therapeutic modalities—necessary to sustain the therapeutic capacity that modern medicine requires. International collaboration, equitable access to diagnostics and therapeutics, and political commitment commensurate with the scale of the crisis are preconditions for success that transcend scientific discovery alone. The window for effective action remains open, but the margin for complacency has narrowed to the point where inaction and catastrophe are increasingly difficult to distinguish.

Conflict of Interest: The author declares no conflict of interest.

Funding: This work received no external funding.

REFERENCES

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10(3):226–236.
2. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; 1:134. doi:10.3389/fmicb.2010.00134
3. World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: WHO; 2014.
4. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
5. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.
6. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance. London: HM Government; 2016.
7. World Health Organization. 2023 antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: WHO; 2024.
8. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–283.

9. Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci USA. 2015;112(18):5649–5654.
10. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579–587.
11. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44(5):681–688.
12. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet. 2013;382(9912):1057–1098.
13. Van Boeckel TP, Glennon EE, Chen D, et al. Reducing antimicrobial use in food animals. Science. 2017;357(6358):1350–1352.
14. Berendonk TU, Manaia CM, Merlin C, et al. Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol. 2015;13(5):310–317.
15. Van Boeckel TP, Pires J, Silvester R, et al. Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science. 2019;365(6459):eaaw1944.
16. Larsson DG, Flach CF. Antibiotic resistance in the environment. Nat Rev Microbiol. 2022;20(5):257–269.
17. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387(10014):168–175.
18. Datta S, Roy S. Perspectives on antimicrobial resistance diagnostics. Clin Microbiol Rev. 2023;36(1):e00168–22.
19. Walsh C. Antibiotics: Actions, Origins, Resistance. Washington DC: ASM Press; 2003.
20. Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2):e00047–19.
21. Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci. 2013;1277(1):91–104.
22. Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012; 3:110.
23. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–4960.
24. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health. Lancet Infect Dis. 2011;11(5):355–362.
25. Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005;57(10):1451–1470.
26. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629–641.
27. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37(8):1563–1571.
28. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354(1):12–31.
29. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46(9):2727–2734.
30. Du D, Wang-Kan X, Neuberger A, et al. Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol. 2018;16(9):523–539.

31. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005;56(1):20–51.
32. Coyne S, Courvalin P, Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother. 2011;55(3):947–953.
33. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic—a vision for applied use. Biochem Pharmacol. 2006;71(7):910–918.
34. Chevalier S, Bouffartigues E, Bodilis J, et al. Structure, function and regulation of Pseudomonas aeruginosa porins. FEMS Microbiol Rev. 2017;41(5):698–722.
35. Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J Infect. 2016;72(2):152–160.
36. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9):563–575.
37. Lebeaux D, Ghigo JM, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 2014;78(3):510–543.
38. Stewart PS, Bjarnsholt T. Risk factors for chronic biofilm-related infection associated with implanted medical devices. Clin Microbiol Infect. 2020;26(8):1034–1038.
39. Lewis K. Persister cells. Annu Rev Microbiol. 2010; 64:357–372.
40. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des. 2015;21(1):5–11.
41. Schaaper RM. Base selection, proofreading, and mismatch repair during DNA replication in Escherichia coli. J Biol Chem. 1993;268(32):23762–23765.
42. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003;52(1):11–17.
43. Colijn C, Cohen T, Ganesh M, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS ONE. 2011;6(3):e18327.
44. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288(5469):1251–1254.
45. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31(4):e00088–17.
46. de la Cruz F, Frost LS, Meyer RJ, Zechner EL. Conjugative DNA metabolism in gram-negative bacteria. FEMS Microbiol Rev. 2010;34(1):18–40.
47. Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol. 2013;303(6–7):298–304.
48. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science. 2011;331(6016):430–434.
49. Chen J, Quiles-Puchalt N, Chiang YN, et al. Genome hypermobility by lateral transduction. Science. 2018;362(6411):207–212.
50. Cambray G, Guerout AM, Mazel D. Integrons. Annu Rev Genet. 2010;44:141–166.
51. Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV. Co-selection of antibiotic and metal resistance. Trends Microbiol. 2006;14(4):176–182.

52. Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evol Appl. 2015;8(3):273–283.
53. Händel N, Schuurmans JM, Brul S, ter Kuile BH. Compensation of the fitness costs of antibiotic resistance by increased expression of transport proteins in Escherichia coli. Antimicrob Agents Chemother. 2013;57(8):3752–3762.
54. Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics. 2000;154(3):985–997.
55. Cassini A, Högberg LD, Plachouras D, et al.; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the EEA in 2015. Lancet Infect Dis. 2019;19(1):56–66.
56. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. 2012;54(9):1253–1261.
57. Teillant A, Gandra S, Barter D, Morgan DJ, Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis. 2015;15(12):1429–1437.
58. Liverani M, Waage J, Barnett T, et al. Understanding and managing zoonotic risk in the new livestock industries. Environ Health Perspect. 2013;121(8):873–877.
59. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14.
60. World Bank. Drug-resistant infections: a threat to our economic future. Washington DC: World Bank Group; 2017.
61. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40.
62. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17.
63. Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: global epidemiology and treatment options. Infect Dis Clin North Am. 2016;30(2):313–333.
64. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.
65. Doern GV, Carroll KC, Diekema DJ, et al. Practical guidance for clinical microbiology laboratories: a comprehensive update on the problem and practice of antibiotic susceptibility testing. Clin Microbiol Rev. 2020;33(1):e00021–19.
66. van Belkum A, Bachmann TT, Lüdke G, et al. Rapid clinical bacteriology and its future impact. Ann Lab Med. 2013;33(1):14–27.
67. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066–18.
68. Doss J, Culbertson K, Hahn D, Camacho J, Barekzi N. A review of phage selection, optimal conditions, and dosing strategies. Viruses. 2017;9(3):70.
69. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection.

Antimicrob Agents Chemother. 2017;61(10):e00954–17.
70. Jesudason T. Advancing the use of bacteriophages to tackle AMR. Lancet Microbe. 2025;6(10).
71. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557.
72. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–250.
73. Mba IE, Nweze EI. Antimicrobial peptides therapy: an emerging alternative for treating drug-resistant bacteria. Yale J Biol Med. 2022;95(4):445–463.
74. 74. Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146–1150.
75. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014;32(11):1141–1145.
76. Sen D, Mukhopadhyay P. Antimicrobial resistance (AMR) management using CRISPR-Cas based genome editing. Gene Genome Ed. 2024; 7:100031.
77. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
78. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001.
79. Ashiru-Oredope D, Hopkins S; English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). Antimicrobial stewardship: English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). J Antimicrob Chemother. 2013;68(11):2421–2423.
80. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Am J Infect Control. 2007;35(10):S65–164.
81. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355(26):2725–2732.
82. Lipworth S, Crook DW, Peto T, Walker AS, Stoesser NE. Whole-genome sequencing for predicting antimicrobial resistance in Gram-negative bacteria. J Antimicrob Chemother. 2019;74(6):1456–1461.
83. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13.
84. Sherry NL, Lee JY, Giulieri SG, et al. Genomics for antimicrobial resistance—progress and future directions. Antimicrob Agents Chemother. 2025;69(5):e01082–24.
85. Rello J, Kalwaje Eshwara V, Lagunes L, et al. A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on clinical impact. Eur J Clin Microbiol Infect Dis. 2019;38(2):319–323.
86. Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016;16(4):500–505.

HOW TO CITE: Ranajeet Patil*, Shivprasad Dhage, Decoding Antimicrobial Resistance: Mechanisms, Evolution, and Therapeutic Challenges, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 2707-2732. https://doi.org/10.5281/zenodo.20132733